Backgroung: This study investigated the efficacy and safety of
TNF antagonists in sarcoid
uveitis in unselected cases. Design: This is a multicentre study on patients with
sarcoidosis who received
TNF antagonists in pneumology and internal medicine departments in France. We present here the subgroup of patients with biopsy-proven sarcoid
uveitis included in the nationwide registry STAT (
Sarcoidosis treated with
TNF AnTagonists). Results: Among the 132 patients included in this multicenter study, 18 patients with refractory
uveitis were treated as a first-line
TNF antagonist with
infliximab (n=14),
adalimumab (n=3) and certolizumab (n=1). Before anti-TNF initiation, the median duration of
sarcoidosis was 42 months and 83% of the patients have been treated with at least one immunosuppressive
drug. Six patients switched for a second-line
TNF antagonist. After a mean time under treatment of 29 months, the treatment resulted in a significant decrease of the ophthalmic extrapulmonary Physician Organ Severity Tool (ePOST) (mean score: 4.2 vs. 2.6) scores and a
steroid sparing effect (29.4±20.7 vs. 6.2±5.2 mg/d). Overall, the ophthalmic response, either complete or partial, was 67%. Nine patients (50%) presented adverse events, including severe infectious complications in 5 patients, which required anti-TNF treatment interruption in 6 cases (33%). Among the 7 responder patients who discontinued anti-TNF
therapy, 71% relapsed. Finally, 12 patients (67%) could continue
TNF antagonist treatment. Conclusions:
TNF antagonists were efficient in 67% of biopsy-proven refractory sarcoid
uveitis. Severe adverse events, mainly infectious complications, were frequent. The high frequency of relapses after anti-TNF-α discontinuation requires a close patient follow-up thereafter. (
Sarcoidosis Vasc Diffuse Lung Dis 2017; 34: 74-80).